ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,730.35
      0.21%
      US Tech 100
      19,446.00
      0.64%
      Dow Jones
      42,154.76
      0.07%
      Brent Oil
      74.285
      0.75%
      Bitcoin
      63,158.97
      -0.27%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Ikena Oncology Inc (IKNA)

      7. Ikena Oncology Inc (IKNA) News

      Ikena Oncology Inc

      Ikena Oncology Inc (IKNA)

      NASDAQ
      1.68
      -0.01
      ( -0.59% )
      Updated: 11:54:18
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      IKNA News

      Official News Only

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      August 08 2024
      IKNA (-0.59%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      July 12 2024
      IKNA (-0.59%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 10 2024
      IKNA (-0.59%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 28 2024
      IKNA (-0.59%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 13 2024
      IKNA (-0.59%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      March 05 2024
      IKNA (-0.59%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      March 05 2024
      IKNA (-0.59%)

      IKNA Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      IKNA under $2
      👍️0
      Monksdream Monksdream 2 months ago
      IKNA under $2
      👍️0
      Monksdream Monksdream 3 months ago
      IKNA under $2
      👍️0
      glenn1919 glenn1919 4 months ago
      IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 6 months ago
      IKNA under $2=
      👍️0
      Monksdream Monksdream 7 months ago
      IKNA under $2
      👍️0
      herbied47 herbied47 10 months ago
      $196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
      Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
      👍️0
      herbied47 herbied47 10 months ago
      Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
      👍️0
      Tacostocks Tacostocks 11 months ago
      It went down, because it didnt have the backing of Money hunt...
      👍️0
      Money hunt Money hunt 11 months ago
      what happened here my short friend
      👍️0
      Tacostocks Tacostocks 11 months ago
      Aged like milk eh
      👍️0
      AJ Freely AJ Freely 1 year ago
      $IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
      To Acquire & Merge w/ Pionyr Immunotherapeutics
      👍️0
      Tartiaboy Tartiaboy 2 years ago
      This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

      I am not too familiar with there lead drug so I am neutral regarding it.
      👍️0
      TrendTrade2016 TrendTrade2016 2 years ago
      IKNA look at this beast
      👍️0
      TrendTrade2016 TrendTrade2016 2 years ago
      IKNA monster
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
      👍️0

      Your Recent History

      NASDAQ
      IKNA
      Ikena Oncology
      Delayed Upgrade Clock